Sign In
Buy SVRA
$5.25
+0 (+0%)
At Close: Jun 03, 2026
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
08:05am, Wednesday, 17'th Dec 2025
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the ma
Savara (NASDAQ:SVRA) & Aclaris Therapeutics (NASDAQ:ACRS) Head-To-Head Survey
05:42am, Tuesday, 16'th Dec 2025
Aclaris Therapeutics (NASDAQ: ACRS - Get Free Report) and Savara (NASDAQ: SVRA - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
08:05am, Thursday, 11'th Dec 2025
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the EPO notified the Company
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the European Patent Office (EPO) h
Savara Inc. (NASDAQ:SVRA) Receives Average Recommendation of “Moderate Buy” from Analysts
03:45am, Saturday, 22'nd Nov 2025
Shares of Savara Inc. (NASDAQ: SVRA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten brokerages that are covering the stock, MarketBeat Ratings reports. One inve
Savara Announces Participation in Upcoming Investor Healthcare Conferences
04:05pm, Thursday, 20'th Nov 2025
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the managem
Savara: A High-Risk Opportunity
06:35am, Sunday, 16'th Nov 2025
Savara, Inc. has rebounded strongly after an FDA setback, aligning on BLA resubmission for molgramostim, its sole clinical candidate for aPAP. Molgramostim showed strong DLCO results in IMPALA-2, with
Savara Reports Third Quarter 2025 Financial Results and Provides Business Update
04:05pm, Wednesday, 12'th Nov 2025
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third qua
New York, New York--(Newsfile Corp. - November 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 2024
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Savara Inc.(SVRA) Shareholders
04:00pm, Friday, 07'th Nov 2025
NEW YORK , Nov. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION:
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara
10:13am, Friday, 07'th Nov 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Savara To Contact Him Directly To Discuss Their Options If you purchased or acquired
Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA
03:19am, Friday, 07'th Nov 2025
LOS ANGELES , Nov. 7, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Savara Inc. ("Savara " or "the Company") (NASDAQ: SVRA ) for violations of §§10(b) an
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
02:22am, Friday, 07'th Nov 2025
LOS ANGELES , Nov. 7, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Savara Inc. ("Savara" or "the Compa
New York, New York--(Newsfile Corp. - November 6, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 2024
Shareholders that lost money on Savara Inc.(SVRA) should contact Levi & Korsinsky about pending Class Action - SVRA
04:19pm, Thursday, 06'th Nov 2025
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit.
